

Author Index (Vol. 69)

- Adams, C.W.M., see Keohane, S.G., 103
Albers, J.J., see Miller, N.E., 123
Amy, R.M., Dolphin, P.J., Pederson, R.A. and Russell, J.C.,
Atherogenesis in two strains of obese rats. The fatty Zucker
and LA/N-corpulent, 199
Aoyama, H., Mori, N. and Mori, W., Effects of melatonin on
genetic hypercholesterolemia in rats, 269
Aursnes, I., Smith, P., Christiansen, E.N., and Berg, K., Factor
analysis of plasma lipoprotein components, 219
Avogaro, P., Cazzolato, G. and Bittolo Bon, G., A question
concerning apo B-48 (Letter to the Editor), 273
- Ball, M., see Jenner, K., 39
Baralle, F.E., see Jenner, K., 39
Baskerville, P., see Shaikh, M., 165
Berg, K., see Aursnes, I., 219
Berguer, R., see Kessel, D., 1
Bittolo Bon, G., see Avogaro, P., 273
Bowyer, D.E., see Jackson, C.L., 115
Brown, W.E., see Tomazic, B.B., 5
Browse, N.L., see Shaikh, M., 165
Bujo, H., see Saito, Y., 161
Bush, R.C., see Jackson, C.L., 115
- Caslake, M.J., see Series, J.J., 233
Cazzolato, G., see Avogaro, P., 273
Christiansen, E.N., see Aursnes, I., 219
Cremer, P., see Siegrist, J., 211
Cruickshank, A., see Series, J.J., 233
Czekelius, P., see Steinmetz, A., 21
- Delcroix, C., see Malmendier, C.L., 51
Demacker, P.N.M., Hijmans, A.G.M., Stalenhoef, A.F.H. and
Van't Laar, A., Studies on the function of hepatic lipase in
the cat after immunological blockade of the enzyme *in vivo*,
173
Demant, T., see Series, J.J., 233
Diehl, A.K., Fuller, J.H., Mattock, M.B., Salter, A.M., El-
Gohari, R. and Keen, H., The relationship of high density
lipoprotein subfractions to alcohol consumption, other
lifestyle factors, and coronary heart disease, 145
Dolphin, P.J., see Amy, R.M., 199
Duffield, R., see Shaikh, M., 165
- El-Gohari, R., see Diehl, A.K., 145
Erkelens, D.W., see Mol, M.J.T.M., 131
- Faris, B., see Ohishi, H., 61
Fears, R., Ferres, H., Haacke, H., Mäder, C. and Parwaresch,
M.R., Decrease in LDL and increase in HDL concentra-
tions in type II hyperlipoproteinaemic patients on low-dose
combination therapy of cholestyramine and Complamin®,
97
Ferres, H., see Fears, R., 97
Franzblau, C., see Ohishi, H., 61
Franzblau, C., see Schreiber, B.M., 69
Friedlander, Y., see Simons, L.A., 139
Fuller, J.H., see Diehl, A.K., 145
- Gevers Leuven, J.A., see Mol, M.J.T.M., 131
Giudici, G., see Jenner, K., 39
Grab, B., see Hong, M.L., 241
Grutman, G.A., see Malmendier, C.L., 51
- Haacke, H., see Fears, R., 97
Hausmann, J., see Ohishi, H., 61
Hess, D., see Ohishi, H., 61
Hijmans, A.G.M., see Demacker, P.N.M., 173
Hollander, W., see Schreiber, B.M., 69
Hong, M.L., James, R.W., Grab, B. and Pometta, D., High
density lipoprotein (HDL) subfractions in cardiovascular
patients with low levels of HDL-cholesterol. Influence of
hyperglyceridaemia on subfraction concentration and com-
position, 241
Hüther, A.M., see Rücker, W., 155
- Jaakkola, O., Kallioniemi, O.-P. and Nikkari, T., Lipoprotein
uptake in primary cell cultures of rabbit atherosclerotic
lesions. A fluorescence microscopic and flow cytometric
study, 257
Jackson, C.L., Bush, R.C. and Bowyer, D.E., Inhibitory effect
of calcium antagonists on balloon catheter-induced arterial
smooth muscle cell proliferation and lesion size, 115
James, R.W., see Hong, M.L., 241
Jenner, K., Sidoli, A., Ball, M., Rodriguez, J.R., Pagani, F.,
Giudici, G., Vergani, C., Mann, J., Baralle, F.E. and
Shoulders, C.C., Characterization of genetic markers in the
3' end of the apo B gene and their use in family and
population studies, 39
- Kaffarnik, H., see Steinmetz, A., 21
Kallioniemi, O.-P., see Jaakkola, O., 257
Kark, J.D., see Simons, L.A., 139
Keen, H., see Diehl, A.K., 145

- Keohane, S.G., Adams, C.W.M. and Poston, R.N., Coronary arterial dimensions and cell populations in ageing man, 103
- Kessel, D. and Berguer, R., Determinants of porphyrin fluorescence emission spectra of atheromatous plaques, 1
- Kilday, C., see Series, J.J., 233
- Klurfeld, D.M., see Kritchevsky, D., 89
- Kobori, S., Nakamura, N., Uzawa, H. and Shichiri, M., Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan, 81
- Kosakai, M., see Ohishi, H., 61
- Kritchevsky, D., Tepper, S.A. and Klurfeld, D.M., Flordipine, a calcium channel blocker, which does not influence lipemia or atherosclerosis in cholesterol-fed rabbits (Preliminary Note), 89
- Kuusi, T., see Sorva, R., 191
- La Ville, A.E., see Shaikh, M., 165
- Lewis, B., see Shaikh, M., 165
- Lontie, J.-F., see Malmendier, C.L., 51
- Madec, Y., see Mainard, F., 225
- Mäder, C., see Fears, R., 97
- Mainard, F., Ozanne, P. and Madec, Y., Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction, 225
- Malmendier, C.L., Lontie, J.-F., Grutman, G.A. and Delcroix, C., Metabolism of apolipoprotein C-III in normolipemic human subjects, 51
- Mann, J., see Jenner, K., 39
- Martin, B.M., see Schreiber, B.M., 69
- Martini, S., see Shaikh, M., 165
- Matschinger, H., see Siegrist, J., 211
- Mattock, M.B., see Diehl, A.K., 145
- Miller, N.E., Rajput-Williams, J., Nanjee, M.N. Samuel, L. and Albers, J.J., Relationship of high density lipoprotein composition to plasma lecithin: cholesterol acyltransferase concentration in men, 123
- Mogayzel, Jr., P.J., see Ohishi, H., 61
- Mol, M.J.T.M., Erkelens, D.W., Gevers Leuven, J.A., Schouten, J.A. and Stalenhoef, A.F.H., Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia, 131
- Mori, N., see Aoyama, H., 269
- Mori, W., see Aoyama, H., 269
- Morisaki, N., see Saito, Y., 161
- Motzny, S., see Steinmetz, A., 21
- Nakamura, N., see Kobori, S., 81
- Nanjee, M.N., see Miller, N.E., 123
- Nikkari, T., see Jaakkola, O., 257
- Nikkilä, E.A., see Sorva, R., 191
- Nikkilä, E.A., see Taskinen, M.-R., 249
- Ohishi, H., Hess, D., Kosakai, M., Schmid, K., Hausmann, J., Mogayzel, Jr., P.J., Faris, B. and Franzblau, C., Glycosaminoglycan content in neonatal rat aortic smooth muscle cell cultures, 61
- Olpin, S.E. and Price, C.P., High density lipoprotein and apolipoprotein A-I in acute phase response (letter to the Editor), 93
- Olzewski, A.J. and Szostak, W.B., Homocysteine content of plasma proteins in ischemic heart disease, 109
- Ozanne, P., see Mainard, F., 225
- Packard, C.J., see Series, J.J., 233
- Pagani, F., see Jenner, K., 39
- Parwaresch, M.R., see Fears, R., 97
- Patsch, W., see Tamai, T., 29
- Pederson, R.A., see Amy, R.M., 199
- Perheentupa, J., see Sorva, R., 191
- Poapst, M., Uffelman, K. and Steiner, G., A question concerning apo B-48: A reply to the letter by P. Avogaro, G.G. Gazzolato and G. Bittolo Bon (Letter to the Editor), 275
- Pometta, D., see Hong, M.L., 241
- Poston, R.N., see Keohane, S.G., 103
- Price, C.P., see Olpin, S.E., 93
- Prop, G., see Rücker, W., 155
- Queral, L.A., see Tomazic, B.B., 5
- Quiney, J.R., see Shaikh, M., 165
- Rajput-Williams, J., see Miller, N.E., 123
- Rodriguez, J.R., see Jenner, K., 39
- Russell, J.C., see Amy, R.M., 199
- Rücker, W., Prop, G. and Hüther, A.M., Antiatherosclerotic and antihyperlipidemic effects of octiminate sodium in rabbits, 155
- Sachinidis, A., see Zidek, W., 185
- Sadovnik, M., see Tomazic, B.B., 5
- Saito, Y., Bujo, H., Morisaki, N., Shirai, K. and Yoshida, S., Proliferation and LDL binding of cultured intimal smooth muscle cells from rabbits, 161
- Salter, A.M., see Diehl, A.K., 145
- Samuel, L., see Miller, N.E., 123
- Schmid, K., see Ohishi, H., 61
- Schonfeld, G., see Tamai, T., 29
- Schouten, J.A., see Mol, M.J.T.M., 131
- Schreiber, B.M., Martin, B.M., Hollander, W. and Franzblau, C., β -VLDL-induced alterations in growth potentiating activity produced by mononuclear phagocytes, 69
- Seidel, D., see Siegrist, J., 211
- Series, J.J., Caslake, M.J., Kilday, C., Cruickshank, A., Demant, T., Packard, C.J. and Shepherd, J., Influence of etofibrate on low density lipoprotein metabolism, 233
- Shaikh, M., Martini, S., Quiney, J.E., Baskerville, P., La Ville, A.E., Browne, N.L., Duffield, R., Turner, P.R. and Lewis, B., Modified plasma-derived lipoproteins in human atherosclerotic plaques, 165
- Shepherd, J., see Series, J.J., 233
- Shichiri, M., see Kobori, S., 81
- Shirai, K., see Saito, Y., 161
- Shoulders, C.C., see Jenner, K., 39
- Sidoli, A., see Jenner, K., 39
- Siegrist, J., Matschinger, H., Cremer, P. and Seidel, D., Atherogenic risk in men suffering from occupational stress, 211

- Simons, J., see Simons, L.A., 139
- Simons, L.A., Friedlander, Y., Simons, J. and Kark, J.D., Familial aggregation of coronary heart disease: partial mediation by high density lipoproteins?, 139
- Smith, P., see Aursnes, I., 219
- Sorva, R., Kuusi, T., Taskinen, M.-R., Perheentupa, J. and Nikkilä, E.A., Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males, 191
- Spieker, C., see Zidek, W., 185
- Stalenhoef, A.F.H., see Demacker, P.N.M., 173
- Stalenhoef, A.F.H., see Mol, M.J.T.M., 131
- Steiner, G., see Poapst, M., 275
- Steinmetz, A., Czekelius, P., Thiemann, E., Motzny, S. and Kaffarnik, H., Changes of apolipoprotein A-IV in the human neonate: evidence for different inductions of apolipoproteins A-IV and A-I in the postpartum period, 21
- Storkebaum, W., see Zidek, W., 185
- Szostak, W.B., see Olszewski, A.J., 109
- Tamai, T., Patsch, W. and Schonfeld, G., Regulation of lipoprotein receptors on a rat hepatoma cell line, 29
- Taskinen, M.-R. and Nikkilä, E.A., Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia, 249
- Taskinen, M.-R., see Sorva, R., 191
- Tepper, S.A., see Kritchevsky, D., 89
- Thiemann, E., see Steinmetz, A., 21
- Tomazic, B.B., Brown, W.E., Queral, L.A. and Sadovnik, M., Physicochemical characterization of cardiovascular calcified deposits. I. Isolation, purification and instrumental analysis, 5
- Turner, P.R., see Shaikh, M., 165
- Uffelman, K., see Poapst, M., 275
- Uzawa, H., see Kobori, S., 81
- Van 't Laar, A., see Demacker, P.N.M., 173
- Vergani, C., see Jenner, K., 39
- Yoshida, S., see Saito, Y., 161
- Zidek, W., Sachinidis, A., Spieker, C. and Storkebaum, W., Effect of hypertensive plasma on Ca^{2+} transport in human neutrophils, 185

Subject Index (Vol. 69)

ACAT inhibitor

- , Atherosclerosis; Rabbits; Cholesterol-rich diet; Octimibate sodium, 155

Acetylated LDL

- , Atherosclerosis; Cell proliferation; Foam cell; Intimal smooth muscle cells; LDL, 161
- , Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Macrophages; Smooth muscle cells, 257

Acipimox

- , Lipoproteins; HDL; Lipolytic enzymes; Hypertriglyceridemia, 249

Ageing

- , Arteritis; Atherosclerosis; Coronary artery; Image analysis; Lymphocyte, 103

Alcohol

- , Lipoproteins; HDL subfractions; Obesity; Coronary heart disease, 145

 α -Amino adipic acid

- , Atherosclerosis; Homocysteine; Human plasma; Homocysteine-cysteine mixed disulfide, 109

Animal model

- , Hepatic triglyceride lipase; Chylomicrons; Lipoproteins; Postprandial phase; Apoproteins, 173

Antihypercholesterolemic effect

- , Melatonin; Genetically hypercholesterolemic rat, 269

Antihypertensive agents

- , Calcium antagonists; Balloon catheter; Smooth muscle cell proliferation; Nifedipine, 115

Aortic smooth muscle cell cultures (rat)

- , Glycosaminoglycans; Ascorbate, 61

Apo A-I

- , HDL subfractions; Hypertriglyceridemia; Cardiovascular patients; Apo A-II, 241

Apo A-II

- , HDL subfractions; Hypertriglyceridemia; Cardiovascular patients; Apo A-I, 241

Apo B genetic markers

- , Hyperlipidemia; Hypervariable region, 39

Apolipoprotein(s)

- , Apolipoprotein E polymorphism; Lipids; Hyperlipoproteinemia type III, 81
- , Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219
- , Familial hypercholesterolemia; Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Lipoproteins, 131

Apolipoproteins, *see also under* Apo

Apolipoprotein C-III turnover

- , Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51

Apolipoprotein E polymorphism

- , Lipids; Apolipoproteins; Hyperlipoproteinemia type III, 81

Apolipoprotein polymorphism

- , Immunoblotting; Umbilical cord apoproteins; Fat absorption, 21

Apoprotein(s)

- , Arterial lipoproteins; Macrophages; Scavenger receptor, 165
- , Hepatic triglyceride lipase; Animal model; Chylomicrons; Lipoproteins; Postprandial phase, 173

- , Myocardial infarction; Lipids; Lipoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225

- , Testosterone; HDL-cholesterol; Hepatic lipase; Lipoprotein lipase, 191

Arterial lipoprotein(s)

- , Apoproteins; Macrophages; Scavenger receptor, 165

Arteritis

- , Ageing; Atherosclerosis; Coronary artery; Image analysis; Lymphocyte, 103

Ascorbate

- , Aortic smooth muscle cell cultures (rat); Glycosaminoglycans, 61

Atherogenic risk

- , Ratio between LDL and HDL; Job insecurity; Shift work, 211

Atheromatous plaques

- , LDL; Porphyrins, 1

Atherosclerosis

- , Acetylated LDL; Fluorescently labelled lipoproteins; LDL; Macrophages; Smooth muscle cells, 257

- , Ageing; Arteritis; Coronary artery; Image analysis; Lymphocyte, 103

- , α -Amino adipic acid; Homocysteine; Human plasma; Homocysteine-cysteine mixed disulfide, 109

- , Apolipoproteins; Cholesterol; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219

- , Calcium channel blockers; Cholesterol; Flordipine; Liver lipids; Serum lipids, 89

- , Cell proliferation; Foam cell; Intimal smooth muscle cells; LDL; Acetylated LDL, 161

- , Growth potentiating activity; Mononuclear phagocytes; Foam cells; β -VLDL, 69

- , Hyperlipidemia; Hyperinsulinemia; Myocardial lesions; Scanning electron microscopy, 199

- , Rabbits; Cholesterol-rich diet; ACAT inhibitor; Octimibate sodium, 155

Balloon catheter

- , Calcium antagonists; Smooth muscle cell proliferation; Nifedipine; Antihypertensive agents, 115

Blood glucose

- , Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Insulin; Cortisol; Vanillylmandelic acid, 225

Bolton-Hunter labeling

- , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Iodine monochloride labeling, 51

Calcium antagonists

- , Balloon catheter; Smooth muscle cell proliferation; Nifedipine; Antihypertensive agents, 115

-Calcium channel blockers

- , Atherosclerosis; Cholesterol; Flordipine; Liver lipids; Serum lipids, 89

Calcium ion

- , Essential hypertension; Neutrophils, 185

Carbonate apatite

- , Cardiovascular mineral; Hydroxyapatite; Octacalcium phosphate; Physicochemical characterization, 5

Cardiovascular mineral

- , Hydroxyapatite; Octacalcium phosphate; Carbonate apatite; Physicochemical characterization, 5

Cardiovascular patients

- , HDL subfractions; Hypertriglyceridemia; Apo A-I; Apo A-II, 241

Cell density

- , Lipoprotein receptor; Regulation; Lipoprotein deficient serum, 29

Cell proliferation

- , Atherosclerosis; Foam cell; Intimal smooth muscle cells; LDL; Acetylated LDL, 161

Cholesterol

- , Apolipoproteins; Atherosclerosis; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219

- , Atherosclerosis; Calcium channel blockers; Flordipine; Liver lipids; Serum lipids, 89

- , Familial hypercholesterolemia; Hydroxymethylglutaryl-coenzyme A reductase; Lipoprotein; Apolipoprotein, 131

Cholesterol-rich diet

- , Atherosclerosis; Rabbits; ACAT inhibitor; Octimibate sodium, 155

Cholestyramine

- , Complamin®; Combination therapy; Hyperlipoproteinemia; LDL; HDL, 97

Chylomicrons

- , Hepatic triglyceride lipase; Animal model; Lipoproteins; Postprandial phase; Apoproteins, 173

Combination therapy

- , Complamin®, Cholestyramine; Hyperlipoproteinemia; LDL; HDL, 97

Complamin®

- , Cholestyramine; Combination therapy; Hyperlipoproteinemia; LDL; HDL, 97

Coronary artery

- , Ageing, Arteritis; Atherosclerosis; Image analysis; Lymphocyte, 103

Coronary heart disease

- , Family history; HDL-cholesterol; Cross-sectional study, 139

- , Lipoproteins, HDL subfractions; Alcohol; Obesity, 145

Cortisol

- , Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Vanillylmandelic acid, 225

Cross-sectional study

- , Coronary heart disease; Family history; HDL-cholesterol, 139

Essential hypertension

- , Calcium ion; Neutrophils, 185

Factor analysis

- , Apolipoproteins; Atherosclerosis; Cholesterol; Fatty acids; Lipoproteins; Triglycerides, 219

Familial hypercholesterolemia

- , Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Lipoprotein; Apolipoprotein, 131

Family history

- , Coronary heart disease; HDL-cholesterol; Cross-sectional study, 139

Fat absorption

- , Apolipoprotein polymorphism; Immunoblotting; Umbilical cord apoproteins, 21

Fatty acids

- , Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Lipoproteins; Triglycerides, 219

Flordipine

- , Atherosclerosis; Calcium channel blockers; Cholesterol; Liver lipids; Serum lipids, 89

Fluorescently labelled lipoproteins

- , Acetylated LDL; Atherosclerosis; LDL; Macrophages; Smooth muscle cells, 257

Foam cell(s)

- , Atherosclerosis; Cell proliferation; Intimal smooth muscle cells; LDL; Acetylated LDL, 161

- , Growth potentiating activity; Mononuclear phagocytes; β -VLDL; Atherosclerosis, 69

Fractional clearance rate

- , LDL catabolism (receptor-mediated and receptor-independent); Synthetic rate; HDL, 233

Genetically hypercholesterolemic rat

- , Melatonin; Antihypercholesterolemic effect, 269

Glycosaminoglycans

- , Aortic smooth muscle cell cultures (rat); Ascorbate, 61

Growth potentiating activity

- , Mononuclear phagocytes; Foam cells; β -VLDL; Atherosclerosis, 69

HDL

- , Complamin®, Cholestyramine; Combination therapy; Hyperlipoproteinemia; LDL, 97

- , LDL catabolism (receptor-mediated and receptor-independent); Fractional clearance rate; Synthetic rate, 233

- , Plasma lecithin:cholesterol acyltransferase; Plasma concentration; HDL-cholesterol, 123
- HDL-cholesterol**
 - , Coronary heart disease; Family history; Cross-sectional study, 139
 - , HDL; Plasma lecithin:cholesterol acyltransferase; Plasma concentration, 123
 - , Testosterone; Apoproteins; Hepatic lipase; Lipoprotein lipase, 191
- HDL subfractions**
 - , Hypertriglyceridemia; Cardiovascular patients; Apo A-I; Apo A-II, 241
 - , Lipoproteins; Alcohol; Obesity; Coronary heart disease, 145
- Hepatic lipase**
 - , Testosterone; HDL-cholesterol; Apoproteins; Lipoprotein lipase, 191
- Hepatic triglyceride lipase**
 - , Animal model; Chylomicrons; Lipoproteins; Postprandial phase; Apoproteins, 173
- High density lipoproteins**, *see also under* HDL
- Homocysteine**
 - , α -Aminoadipic acid; Atherosclerosis; Human plasma; Homocysteine-cysteine mixed disulfide, 109
- Homocysteine-cysteine mixed disulfide**
 - , α -Aminoadipic acid; Atherosclerosis; Homocysteine; Human plasma, 109
- Human plasma**
 - , α -Aminoadipic acid; Atherosclerosis; Homocysteine; Homocysteine-cysteine mixed disulfide, 109
- Hydroxyapatite**
 - , Cardiovascular mineral; Octacalcium phosphate; Carbonate apatite; Physicochemical characterization, 5
- Hydroxymethylglutaryl-coenzyme A reductase**
 - , Familial hypercholesterolemia; Cholesterol; Lipoprotein; Apolipoprotein, 131
- Hyperinsulinemia**
 - , Atherosclerosis; Hyperlipidemia; Myocardial lesions; Scanning electron microscopy, 199
- Hyperlipidemia**
 - , Apo B genetic markers; Hypervariable region, 39
 - , Atherosclerosis; Hyperinsulinemia; Myocardial lesions; Scanning electron microscopy, 199
- Hyperlipoproteinemia**
 - , Complamin[®]; Cholestyramine; Combination therapy; LDL; HDL, 97
- Hyperlipoproteinemia type III**
 - , Apolipoprotein E polymorphism; Lipids; Apolipoproteins, 81
- Hypertriglyceridemia**
 - , HDL subfractions; Cardiovascular patients; Apo A-I; Apo A-II, 241
 - , Lipoproteins; HDL; Acipimox; Lipolytic enzymes, 249
- Hypervariable region**
 - , Hyperlipidemia; Apo B genetic markers, 39
- Image analysis**
 - , Ageing; Arteritis; Atherosclerosis; Coronary artery; Lymphocyte, 103
- Immunoblotting**
 - , Apolipoprotein polymorphism; Umbilical cord apoproteins; Fat absorption, 21
- Insulin**
 - , Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Cortisol; Vanillylmandelic acid, 225
- Intimal smooth muscle cells**
 - , Atherosclerosis; Cell proliferation; Foam cell; LDL; Acetylated LDL, 161
- In vivo kinetics**
 - , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51
- Iodine monochloride labeling**
 - , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling, 51
- Job insecurity**
 - , Atherogenic risk; Ratio between LDL and HDL; Shift work, 211
- LDL**
 - , Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; Macrophages; Smooth muscle cells, 257
 - , Atheromatous plaques; Porphyrins, 1
 - , Atherosclerosis; Cell proliferation; Foam cell; Intimal smooth muscle cells Acetylated LDL, 161
 - , Complamin[®]; Cholestyramine; Combination therapy; Hyperlipoproteinemia; HDL, 97
- LDL catabolism (receptor-mediated and receptor-independent)**
 - , Fractional clearance rate; Synthetic rate; HDL, 233
- Lipids**
 - , Apolipoprotein E polymorphism; Apolipoproteins; Hyperlipoproteinemia type III, 81
 - , Myocardial infarction; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
- Lipolytic enzymes**
 - , Lipoproteins; HDL; Acipimox; Hypertriglyceridemia, 249
- Lipoprotein(s)**
 - , Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Triglycerides, 219
 - , Familial hypercholesterolemia; Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Apolipoprotein, 131
 - , HDL; Acipimox; Lipolytic enzymes; Hypertriglyceridemia, 249
 - , HDL subfractions; Alcohol; Obesity; Coronary heart disease, 145
 - , Hepatic triglyceride lipase; Animal model; Chylomicrons; Postprandial phase; Apoproteins, 173
 - , Myocardial infarction; Lipids; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
- Lipoprotein deficient serum**
 - , Lipoprotein receptor; Regulation; Cell density, 29
- Lipoprotein fractions**
 - , Apolipoprotein C-III turnover; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51

Lipoprotein lipase

- , Testosterone; HDL-cholesterol; Apoproteins; Hepatic lipase, 191

Lipoprotein receptor

- , Regulation; Cell density; Lipoprotein deficient serum, 29

Liver lipids

- , Atherosclerosis; Calcium channel blockers; Cholesterol; Flordipine; Serum lipids, 89

Low density lipoproteins, *see also under* LDL**Lymphocyte**

- , Ageing; Arteritis; Atherosclerosis; Coronary artery; Image analysis, 103

Macrophages

- , Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Smooth muscle cells, 257
- , Arterial lipoproteins; Apoproteins; Scavenger receptor, 165
- Melatonin
- , Genetically hypercholesterolemic rat; Antihypercholesterolemic effect, 269

Metabolism

- , Apolipoprotein C-III turnover; Lipoprotein fractions; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51

Mononuclear phagocytes

- , Growth potentiating activity; Foam cells; β -VLDL; Atherosclerosis, 69

Myocardial infarction

- , Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225

Myocardial lesions

- , Atherosclerosis; Hyperlipidemia; Hyperinsulinemia; Scanning electron microscopy, 199

Neutrophils

- , Calcium ion; Essential hypertension, 185

Nifedipine

- , Calcium antagonists; Balloon catheter; Smooth muscle cell proliferation; Antihypertensive agents, 115

Normal subjects

- , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51

Obesity

- , Lipoproteins; HDL subfractions; Alcohol; Coronary heart disease, 145

Octacalcium phosphate

- , Cardiovascular mineral; Hydroxyapatite; Carbonate apatite; Physicochemical characterization, 5

Ocimbate sodium

- , Atherosclerosis; Rabbits; Cholesterol-rich diet; ACAT inhibitor, 155

Physicochemical characterization

- , Cardiovascular mineral; Hydroxyapatite; Octacalcium phosphate; Carbonate apatite, 5

Plasma

- , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51

Plasma concentration

- , HDL; Plasma lecithin:cholesterol acyltransferase; HDL-cholesterol, 123

Plasma lecithin:cholesterol acyltransferase

- , HDL; Plasma concentration; HDL-cholesterol, 123

Porphyrins

- , Atheromatous plaques, LDL, 1

Postprandial phase

- , Hepatic triglyceride lipase; Animal model; Chylomicrons; Lipoproteins; Apoproteins, 173

Rabbits

- , Atherosclerosis; Cholesterol-rich diet; ACAT inhibitor; Ocimbate sodium, 155

Ratio between LDL and HDL

- , Atherogenic risk; Job insecurity; Shift work, 211

Regulation

- , Lipoprotein receptor; Cell density; Lipoprotein deficient serum, 29

Scanning electron microscopy

- , Atherosclerosis; Hyperlipidemia; Hyperinsulinemia; Myocardial lesions, 199

Scavenger receptor

- , Arterial lipoproteins; Apoproteins; Macrophages, 165

Serum lipids

- , Atherosclerosis; Calcium channel blockers; Cholesterol; Flordipine; Liver lipids, 89

Shift work

- , Atherogenic risk; Ratio between LDL and HDL; Job insecurity, 211

Smooth muscle cell(s)

- , Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Macrophages, 257

Smooth muscle cell proliferation

- , Calcium antagonists; Balloon catheter; Nifedipine; Antihypertensive agents, 115

Synthetic rate

- , LDL catabolism (receptor-mediated and receptor-independent); Fractional clearance rate; HDL, 233

Testosterone

- , HDL-cholesterol; Apoproteins; Hepatic lipase; Lipoprotein lipase, 191

Triglycerides

- , Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Lipoproteins, 219

Umbilical cord apoproteins

- , Apolipoprotein polymorphism; Immunoblotting; Fat absorption, 21

Urine

- , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Bolton-Hunter labeling; Iodine monochloride labeling, 51

Vanillylmandelic acid

- , Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol, 225

Very low density lipoproteins, *see also under* VLDL **β -VLDL**

- , Growth potentiating activity; Mononuclear phagocytes; Foam cells; Atherosclerosis, 69

(Contents continued from back cover)

Atherogenic risk in men suffering from occupational stress (ATH 04071)	
J. Siegrist, H. Matschinger, P. Cremer and D. Seidel (F.R.G.)	211
Factor analysis of plasma lipoprotein components (ATH 04076)	
I. Aursnes, P. Smith, E.N. Christiansen and K. Berg (Norway)	219
Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction (ATH 04077)	
F. Mainard, P. Ozanne and Y. Madec (France)	225
Influence of etofibrate on low density lipoprotein metabolism (ATH 04078)	
J.J. Series, M.J. Caslake, C. Kilday, A. Cruickshank, T. Demant, C.J. Packard and J. Shepherd (U.K.)	233
High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hypertriglyceridaemia on subfraction concentration and composition (ATH 04079)	
M.L. Hong, R.W. James, B. Grab and D. Pometta (Switzerland)	241
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia (ATH 04080)	
M.-R. Taskinen and E.A. Nikkilä (Finland)	249
Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study (ATH 04081)	
O. Jaakkola, O.-P. Kallioniemi and T. Nikkari (Finland)	257
Effects of melatonin on genetic hypercholesterolemia in rats (ATH 04066)	
H. Aoyama, N. Mori and W. Mori (Japan)	269
<i>Letters to the Editor</i>	
A question concerning apo B-48 (ATH 04072)	
P. Avogaro, G. Cazzolato and G. Bittolò Bon	273
A question concerning apo B-48. A reply to the letter by P. Avogaro, G. Cazzolato and B. Bittolò Bon (ATH 04073)	
M. Poapst and K.U.G. Steiner	275
<i>Erratum</i>	277
<i>Announcements</i>	279
<i>Author Index (Vol. 69)</i>	281
<i>Subject Index (Vol. 69)</i>	284

